Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27672504 | 0.81 | GRIN2D (0.33) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4713608 | 0.76 | GRIN2D (0.33) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20526370 | 0.76 | GRIN2D (0.33) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4712867 | 0.73 | ALDH1A1 (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4709940 | 0.73 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1497426 | 0.73 | LMNA (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9146369 | 0.70 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4710024 | 0.70 | GLA (0.32) | — | |
| SCHEMBL4711516 | 0.68 | THRB (0.34) | GAAEPHX2HTT | |
| SCHEMBL1717809 | 0.67 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1398309-B1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6833388-B2 | 1,3-adamantanedicarboxylic acid-bis(2'-alkyl-2'-adamantyl)-esters; photoresist additive; resin heat resistance improver; pharmaceutical and agrochemical intermediates | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20040157923-A1 | Novel adamantane derivative | IDEMITSU KOSAN CO. LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1398309-A1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157923-A1 | Novel adamantane derivative | TAS1R1, TAS2R1, ADORA1 | GAA 939/4885GRIN2D 782/4885GRIN3B 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.